Stockholders' Equity (Tables)

3 Months Ended

Apr. 30, 2026

Equity [Abstract]

Schedule of Capital Units

Common stock reserved for issuance as of April 30, 2026 and January 31, 2026 are presented as follows:

	As of
	April 30, 2026	January 31, 2026
Stock options issued and outstanding	37,455,860	39,283,485
RSUs issued and outstanding	18,806,310	9,311,201
Shares of common stock available for future grants	39,206,459	37,811,841
Shares available for issuance under the 2025 Employee Stock Purchase Plan ("ESPP")	7,491,747	5,000,000
Total common stock reserved for issuance	102,960,376	91,406,527

Schedule of Share-Based Payment Arrangement, Option, Activity

The following table presents stock option activity for the three months ended April 30, 2026 (in thousands, except price per share, share and years data):

	Number of Stock Options Outstanding	Weighted-Average Exercise Price per Share		Weighted- Average Remaining Contractual Life (Years)	Aggregate Intrinsic Value
Balance as of January 31, 2026	39,283,485	$	13.91	5.7	$	55,743
Granted	1,010,099	$	9.97
Exercised	(2,451,289)	$	6.64		$	16,981
Cancelled/forfeited/expired	(386,435)	$	16.74
Balance as of April 30, 2026	37,455,860	$	14.25	5.7	$	145,849
Vested and expected to vest as of April 30, 2026	37,455,860	$	14.25	5.7	$	145,849
Exercisable as of April 30, 2026	30,776,070	$	13.32	5.3	$	135,182

Schedule of Share-Based Payment Arrangement, Restricted Stock Unit, Activity

The following table presents the activity related to RSUs for the three months ended April 30, 2026:

	Number of Shares Subject to RSUs	Weighted-Average Grant Date Fair Value
Unvested balance as of January 31, 2026	9,311,201	$	22.23
Granted	10,915,113	$	14.96
Forfeited	(474,657)	$	22.71
Vested	(945,347)	$	22.03
Unvested and outstanding as of April 30, 2026	18,806,310	$	18.01

Schedule of Stock-based Compensation

Stock-based compensation is included in the following components of expenses within the condensed consolidated statements of operations (in thousands):

	Three Months Ended April 30,
	2026		2025
Cost of revenue	$	1,720	$	1,047
Research and development	10,964		6,898
Sales and marketing	8,255		3,595
General and administrative	16,373		5,720
Total stock-based compensation expense, net of amounts capitalized	$	37,312	$	17,260
Capitalized stock-based compensation	1,074		570
Total stock-based compensation cost	$	38,386	$	17,830